Where it trades today
trading 84% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- HUM trades at 36.5x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- HUM carries a beta of 0.74, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- HUM is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in HUM.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for HUM come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for HUM. Last refresh: Sep 18, 2026, 10:56 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Humana Inc. does
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit…
What analysts expect
HUM carries a buy consensus from 23 analysts, with an average price target of $419.04 versus $386.22 today (+8.5%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
HUM generated $145.68B in trailing revenue (26.2% year over year), with a 0.9% net margin, and $1.94B of free cash flow, supported by $9.13B of net cash.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $129.66B | — | — | $1.19B | $9.87 | $375.00M |
| 2024 | $117.76B | — | — | $1.21B | $10.01 | $2.39B |
| 2023 | $106.37B | — | — | $2.49B | $20.09 | $2.98B |
| 2022 | $92.87B | — | — | $2.81B | $22.20 | $3.45B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
HUM beside the healthcare names it is usually measured against.
What the chart is saying
Humana Inc. trades at $386.22, 9.9% below its 52-week high. With a beta of 0.74, it shows less sensitivity to what the wider market does.
Questions people ask about it
Is HUM a good buy right now?
Humana Inc. trades at 36.5x earnings. This is above market average, reflecting growth expectations. Current risk level is Medium based on 23.3% volatility.
Does HUM pay dividends?
Yes, Humana Inc. offers a dividend yield of 0.92%. That is roughly $3.55 per share a year.
How volatile is HUM?
With 30-day annualized volatility of 23.3% and beta of 0.74, HUM is classified as Medium risk. The stock tends to be more stable than the market average.
What is the analyst price target for HUM?
The average analyst price target for Humana Inc. (HUM) is $419.04 based on 23 analyst estimates, about 8.5% above the current price of $386.22. The published range runs from $280.00 to $513.00.
How much revenue does HUM generate?
Humana Inc. reported $145.68B in trailing twelve-month revenue. Revenue growth is running at 26.2% year over year. Net margin sits at 0.9%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.